| Patent application number | Description | Published |
|---|
| 20080274192 | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor - A pharmaceutical composition comprising the compound 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or a pharmaceutically acceptable salt or solvate thereof, in an amorphous form. | 11-06-2008 |
| 20090118328 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase - A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment. | 05-07-2009 |
| 20090142401 | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 06-04-2009 |
| 20100003331 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE - A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier. | 01-07-2010 |
| 20100062073 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein. | 03-11-2010 |
| 20100068276 | MULTIPARTICULATES OF SPRAY-COATED DRUG AND POLYMER ON A MELTABLE CORE - A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate. | 03-18-2010 |
| 20100089186 | Device for evaluation of pharmaceutical compositions - A membrane-permeation test for evaluating pharmaceutical compositions is described. The method comprises the following steps: (1) providing a microporous membrane having a plurality of pores, the membrane having a feed side and a permeate side, wherein the feed side of the membrane is in fluid communication with the feed solution, and wherein the permeate side of the membrane is in fluid communication with a permeate solution; (2) administering a pharmaceutical composition to an aqueous solution to form a feed solution; and (3) measuring the concentration of drug in the permeate solution; wherein the feed side of the membrane is hydrophilic, and/or wherein the permeate solution comprises an organic fluid. | 04-15-2010 |
| 20100119612 | NANOPARTICLES COMPRISING NON-CRYSTALLINE DRUG - A pharmaceutical composition comprises nanoparticles comprising a core of non-crystalline drug and surface stabilizers consisting of a phospholipid and a bile salt. | 05-13-2010 |
| 20100233272 | DOSAGE FORMS COMPRISING CELECOXIB PROVIDING BOTH RAPID AND SUSTAINED PAIN RELIEF - A pharmaceutical dosage form comprising celecoxib and a pharmaceutically acceptable carrier, the dosage form when initially administered to at least 12 human patients in the fasted state in a crossover study providing: (a) a mean blood plasma concentration of celecoxib within 0.5 hour after administration (C | 09-16-2010 |
| 20110002989 | METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD - The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time curve (AUC | 01-06-2011 |
| 20110027372 | MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 02-03-2011 |
